Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, with particular emphasis on pediatric endocrinology and other rare endocrine and metabolic disorders. Its 2025 press releases highlight a growing portfolio of eight commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, along with late-stage candidates such as ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector.
The ETON news feed features updates on FDA regulatory milestones, product launches, financial results, and corporate developments. Examples include the U.S. FDA approval of KHINDIVI (hydrocortisone) Oral Solution for pediatric adrenocortical insufficiency, the FDA’s acceptance of the New Drug Application for ET-600 (desmopressin oral solution) with a specified PDUFA target action date, and quarterly earnings reports detailing product sales growth and pipeline investment. The company also reports on its acquisition and relaunch of INCRELEX and GALZIN, and on its inclusion in the Russell 2000 and Russell 3000 indexes.
Investors following ETON news can track how Eton’s commercial portfolio and pipeline evolve through regulatory decisions, label expansion efforts, clinical study plans, and conference participation. Regular press releases also discuss non-GAAP metrics such as Adjusted EBITDA, providing additional context for financial performance. This news page aggregates these company-issued updates so readers can review Eton’s rare disease strategy, key product milestones, and ongoing engagement with the healthcare and investment communities.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced FDA approval for ZONISADE™ (zonisamide oral suspension) on July 18, 2022. This marks the eighth product approval for Eton's development team. ZONISADE™ will be commercialized by Azurity Pharmaceuticals, resulting in a $5 million milestone payment to Eton, along with royalties on net sales and potential commercial milestones totaling up to $15 million. The funds from this launch will help expand Eton's rare disease portfolio.
Dr. Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals for approximately $5 million upfront, with potential contingent payments of $45 million. The acquisition includes the NDAs for Biorphen® and Rezipres® injections and aims to enhance Dr. Reddy’s institutional business in the U.S. market, where the total addressable market for these products is estimated at $174 million for the year ending April 2022. This move supports Dr. Reddy’s commitment to expanding affordable medications.
Eton Pharmaceuticals has sold its rights to Biorphen®, Rezipres®, and Cysteine Hydrochloride products to Dr. Reddy's Laboratories for potential payments of up to $50 million. This strategic move allows Eton to concentrate on its core business of rare disease treatments. Eton's royalty portfolio is set to earn up to $70 million from milestone payments and royalties on additional products. The company retains its focus on four rare disease candidates, enhancing its position in the pharmaceutical market aimed at underserved conditions.
Eton Pharmaceuticals (ETON) reported a strong financial performance for Q1 2022, achieving $2.2 million in product sales and royalties, a 100% increase from Q4 2021. The company attained final FDA approval for cysteine injection and submitted a Prior Approval Supplement for its Biorphen vial product, expecting an action date in August 2022. Eton's commercial products, such as ALKINDI SPRINKLE and carglumic acid, are performing well, with strong growth and market share projections. However, Eton reported a net loss of $5.3 million for the quarter.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) will report its first quarter 2022 financial results on May 12, 2022. A conference call and live audio webcast will occur at 4:30 p.m. ET, allowing management to discuss results and take live questions from participants. Investors can also submit questions via email. The live webcast is accessible on Eton's investor website, with an archived version available for 30 days post-event. Eton specializes in treatments for rare diseases and currently holds royalties from seven FDA-approved products, with three more awaiting FDA review.
Eton Pharmaceuticals (Nasdaq: ETON) announced the appointment of James Gruber as Chief Financial Officer, effective immediately, following the retirement of Wilson Troutman. Mr. Troutman will assist in the transition until the end of May. Gruber brings over 20 years of financial experience, including a significant tenure at Horizon Therapeutics where he managed financial operations during substantial growth. Eton, focused on rare disease treatments, currently owns or earns royalties from seven FDA-approved products and has three additional submissions pending.
Eton Pharmaceuticals (Nasdaq: ETON) has received FDA approval for its cysteine hydrochloride ANDA, a bioequivalent generic to Exela Pharma's Elcys™, securing 180 days of exclusivity. Cysteine is essential for newborns, used as an additive in amino acid solutions. Following Exela's price hike from $22 to $82 per vial, Eton aims to offer a cost-effective alternative. The FDA approval comes amid ongoing litigation regarding the validity of Exela’s patents, with a decision expected in Q3 2022. The cysteine market exceeds $50 million annually, positioning Eton for substantial revenue opportunities.
Eton Pharmaceuticals reported a fourth quarter 2021 revenue of $6.1 million, including a $5 million milestone payment from the launch of EPRONTIA. The company achieved a net income of $1 million and EPS of $0.04, compared to a net loss of $7.7 million in the same quarter last year. The launch of carglumic acid is exceeding expectations, and the partnership with Tolmar for ALKINDI SPRINKLE is driving new prescriptions. Eton has six FDA-approved products in the launch phase, with four more awaiting approval.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. announced the commercial launch of Rezipres® (ephedrine hydrochloride) injection, approved for treating hypotension during anesthesia. The ready-to-use formulation aims to replace unapproved compounded options, enhancing safety for hospitals. The ephedrine injection market saw a 24% growth in 2021, reaching $86 million. Rezipres is supplied in a 5mL ampule and can be ordered through major wholesalers. Eton retains ownership of the FDA New Drug Application.
Eton Pharmaceuticals, Inc (Nasdaq: ETON) announced its fourth quarter 2021 financial results will be reported on March 16, 2022. Management will host a conference call and live audio webcast for investors at 7:00 p.m. ET due to ongoing litigation regarding their cysteine product. Investors can submit questions via email prior to or during the call. Eton currently holds six FDA-approved products and has four others submitted for approval, emphasizing their focus on rare diseases.